Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors.

Trial Profile

Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Erlotinib (Primary) ; Sorafenib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 05 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top